Andrew Lichtenberg

Primary Focus & Experience

Mr. Lichtenberg’s practice includes both high-stakes civil litigation and regulatory investigations. His litigation work focuses on class actions and other complex commercial litigation. He has litigated regarding a variety of subjects, often including finance, technology, or both. His regulatory work focuses on the representation of entities and individuals before criminal and financial regulators, including the Department of Justice (DOJ), the Securities and Exchange Commission (SEC), and the Commodity Futures Trading Commission (CFTC).

Representative matters include:

• Won directed verdict dismissing alter ego and successor-in-interest claims against pharmaceutical development private equity company and one of its founders.
• Won summary judgment for major technology company defendant in patent infringement case regarding mobile devices.
• Won dismissal of $210M royalty refund claim for pharmaceutical company in patent licensing dispute.
• Represented foreign bank in global regulatory investigations relating to alleged manipulation of London Interbank Offered Rate (LIBOR) and Euro Interbank Offered Rate (EURIBOR), ultimately reaching a coordinated resolution with numerous regulators (DOJ, CFTC, and others). Continue to represent bank in follow-on class actions asserting manipulation, fraud, and collusion claims, in U.S. and abroad. Defeated class certification in one of those actions after all of Plaintiffs’ experts were excluded.
• Represented founder and former CEO of fintech company in securities and derivative actions and SEC investigation.
• Represent Big Four auditors in SEC and PCAOB investigations and civil actions.

Recognitions & Accomplishments

Mr. Lichtenberg has been recognized repeatedly for his pro bono work, primarily on behalf of immigrants. He received the Legal Aid Society’s Pro Bono Publico Award in 2011 and 2016, and Milbank’s Pro Bono Achievement Award in 2012, 2019, and 2020.

Before attending law school, Mr. Lichtenberg was an economic analyst at the New York State Office of the Attorney General, where he developed models and programs to estimate the impact of illegal activity with the Investor Protection, Antitrust and Healthcare Bureaus.